ADENOSINE Drug Patent Profile

When do Adenosine patents expire, and when can generic versions of Adenosine launch?

Adenosine is a drug marketed by Am Regent, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hikma, Mylan Labs Ltd, Pharmobedient, Rising, Teva Pharms Usa, Wockhardt, Avet Lifesciences, Eugia Pharma, Hospira, Meitheal, and Mylan Asi. and is included in twenty-one NDAs.

The generic ingredient in ADENOSINE is adenosine. There are twenty-six drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adenosine

A generic version of ADENOSINE was approved as adenosine by HIKMA on June 16^th, 2004.

Summary for ADENOSINE

US Patents:	0
Applicants:	15
NDAs:	21
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	123
Clinical Trials:	662
Patent Applications:	5,219
Drug Prices:	Drug price information for ADENOSINE
DailyMed Link:	ADENOSINE at DailyMed

See drug prices for ADENOSINE

Recent Clinical Trials for ADENOSINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nandakumar Narayanan	PHASE1
Assiut University	NA
Vanderbilt University Medical Center	PHASE1

See all ADENOSINE clinical trials

Pharmacology for ADENOSINE

Drug Class	Adenosine Receptor Agonist
Mechanism of Action	Adenosine Receptor Agonists

Medical Subject Heading (MeSH) Categories for ADENOSINE

Analgesics

Anti-Arrhythmia Agents

Purinergic P1 Receptor Agonists

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for ADENOSINE

C01EB	Other cardiac preparations
C01E	OTHER CARDIAC PREPARATIONS
C01	CARDIAC THERAPY
C	Cardiovascular system

Paragraph IV (Patent) Challenges for ADENOSINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADENOSCAN	Injection	adenosine	3 mg/mL, 20 mL and 30 mL vials	020059	1	2005-04-18

US Patents and Regulatory Information for ADENOSINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	090450-002	Oct 2, 2014	AP	RX	No	No
Am Regent	ADENOSINE	adenosine	INJECTABLE;INJECTION	090010-001	Apr 28, 2009		DISCN	No	No
Eugia Pharma	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	205331-002	Nov 2, 2017	AP	RX	No	No
Meitheal	ADENOSINE	adenosine	SOLUTION;INTRAVENOUS	077425-002	Aug 29, 2013	AP	RX	No	Yes
Hikma	ADENOSINE	adenosine	INJECTABLE;INJECTION	076500-001	Jun 16, 2004	AP	RX	No	No
Gland	ADENOSINE	adenosine	INJECTABLE;INJECTION	206778-001	Feb 16, 2018	AP	RX	No	No

ADENOSINE Market Analysis and Financial Projection

Last updated: February 5, 2026

Market Dynamics for Adenosine

Adenosine is a naturally occurring nucleoside involved in numerous physiological processes, mainly used as an antiarrhythmic agent to treat certain types of supraventricular tachycardia. Its market is driven by specific clinical applications, regulatory approvals, and clinical practice guidelines.

Clinical Usage and Market Drivers

• Indications: Adenosine primarily treats paroxysmal supraventricular tachycardia (PSVT). It is administered during acute episodes, predominantly in hospital settings.
• Administration: The drug is administered via intravenous injection, which constrains usage to healthcare facilities.
• Market Penetration: Its use depends on cardiology practice standards and emergency response protocols.

Key Factors Influencing Market Dynamics

• Clinical Guidelines: Changes in clinical practice guidelines influence adoption rates. Routine use in emergency settings ensures steady demand.
• Competitors: Alternative therapies, including calcium channel blockers and beta-blockers, compete with adenosine, especially for patients with contraindications or intolerance.
• Regulatory Landscape: Approval status in different regions impacts availability; currently, adenosine is approved in multiple markets including the US and EU.
• Healthcare Infrastructure: Hospital workflow and emergency response protocols affect utilization rates.

Market Size and Growth

• Global Market Value (2022): Estimated to be around $250 million.
• Compound Annual Growth Rate (CAGR): Projected at 3-4% over the next five years, driven by increased hospital admissions for arrhythmia management.
• Regional Trends: The US dominates the market, accounting for approximately 60% of sales, due to high healthcare expenditure and advanced medical infrastructure. Europe and Asia-Pacific follow, with growth prospects linked to expanding healthcare access.

Regulatory and Reimbursement Landscape

• Approval Status: Widely approved, with formulations available in injectable forms.
• Reimbursement: Coverage varies by country; in the US, Medicare and private insurers generally reimburse emergency drug use.
• Pricing Trends: Pricing tends to stabilize due to generic availability and in-hospital administration settings.

---

Financial Trajectory of Adenosine

Revenue Composition

• Product Revenue: Primarily generated from hospital purchases; minimal outpatient or retail sales.
• Pricing: Average wholesale price (AWP) ranges from $7 to $12 per vial, depending on jurisdiction and formulation.

Cost Structure and Profitability

• Manufacturing Costs: Low, owing to synthetic production processes.
• Market Margins: Moderate, with profitability affected by generic competition and procurement negotiations.

R&D and Pipeline Prospects

• Current R&D: Limited, as the drug has been on the market for decades with established formulations.
• Pipeline Candidates: No significant new formulations or derivatives are in late-stage development, suggesting limited innovation potential.

Market Risks and Opportunities

• Risks:
  • Emergence of new therapies or devices for arrhythmia management.
  • Changes in clinical guidelines reducing reliance on adenosine.
  • Supply chain disruptions affecting manufacturing.
• Opportunities:
  • Potential for broader emergency medical protocol integration.
  • Manufacturing cost reductions enabling wider access.

Financial Outlook

• Short-term (1-3 years): Stable revenue trajectory with minor growth.
• Long-term (3-5 years): Potential plateau unless new indications or formulations emerge.

---

Key Takeaways

• The adenosine market is niche, focused on acute arrhythmia treatment within hospital environments.
• Market size is approximately $250 million, with modest growth expected.
• Dominated by the US, with expansion dependent on healthcare infrastructure and clinical practice shifts.
• Revenue mainly derives from hospital procurement, with generic competition limiting margins.
• Innovation prospects are limited; the current market appears mature.

---

FAQs

1. What is the primary clinical use of adenosine?
   It is used to treat paroxysmal supraventricular tachycardia (PSVT) by restoring normal heart rhythm acutely.

2. Are there significant competitors to adenosine in arrhythmia treatment?
   Yes. Calcium channel blockers and beta-blockers serve as alternatives, especially for patients who cannot receive adenosine.

3. What factors could impact future revenue for adenosine?
   Changes in clinical guidelines, the advent of new therapies, or shifts in emergency treatment protocols could reduce demand.

4. Is there ongoing research to develop new formulations or indications?
   Current R&D activity is minimal; the drug’s long-standing approval suggests limited pipeline development.

5. How does the regulatory environment influence adenosine's market?
   Widespread approval facilitates market stability; however, regional regulatory changes can impact access and reimbursement policies.

---

References

1. Market data sourced from IQVIA (2022), estimated global market value and regional distribution.
2. Price range based on publicly available hospital procurement pricing reports.
3. Industry forecasts from Evaluate Pharma (2022) on CAGR and growth prospects.
4. Approval status and clinical guidelines from FDA and EMA publications.
5. Reimbursement and healthcare infrastructure insights from WHO reports (2022).